(Reuters) - A COVID-19 vaccine developed by CanSino Biologics Inc and China's military research unit has shown to be safe and induced immune response in most of the recipients, researchers said on Monday.
The CanSino candidate, named Ad5-nCOV, is one of a handful of vaccines that have shown some promise in human testing and are gearing up for late-stage trials, along with projects involving Moderna Inc, BioNTech SE and Inovio Pharmaceuticals Inc.
Already a subscriber? Log in.
Limited time offer:
Just RM5 per month.
Cancel anytime. No ads. Auto-renewal. Unlimited access to the web and app. Personalised features. Members rewards.
Follow us on our official WhatsApp channel for breaking news alerts and key updates!
